Company intelligence / Profile preview
AL-S Pharma AG
Schlieren, Zürich, Switzerlandtvm-lifescience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AP-101 has demonstrated to be safe and well-tolerated in the ongoing Phase 1 single ascending dose study in familial and sporadic ALS patients. The company has initiated a multicenter, placebo-controlled Phase 2 clinical trial to evaluate AP-101 in patients with ALS[2][7].
- Therapeutic areas
- Neurology
- Modalities
- Human monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NeurimmuneTVM Capital Life ScienceChorus (a research and development unit within Eli Lilly and Company)
Beyond the preview
Go deeper on AL-S Pharma AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL-S Pharma AG.